[Value of XXXX in treatment of @entity3085 in head-neck tumors].

@entity1 @entity66 @entity7782 @entity5 @entity957 @entity448 @entity3085 @entity2268 @entity7783 @entity6303 @entity10 @entity21668
Mortality of 70% of all @entity1 with @entity5 in the head and neck is linked with @entity448 and @entity3085 . Two reasons for @entity3085 are well known: 1. @entity66 and local therapy preventing oral nutrition and 2. advanced @entity5 activating biochemical pathways of proteolysis, lipolysis, and gluconeogenesis. Five groups of substances are now used to treat @entity5 -induced @entity3085 : corticosteroids, progestational drugs, @entity7782 , @entity7783 , and @entity21668 . Between 1992 and 1993 we treated 38 @entity1 suffering from @entity3085 due to advanced @entity5 of the head and neck with 160 mg @entity6303 per day for four months. The increase in body weight was significant after eight weeks. The mean increase after full therapy was 4.58 +/- 3.19 kg. Treatment of the five @entity1 in the series was very successful and all achieved their former body weight. @entity6303 therapy was best started after assuring enteral nutrition. Significant adverse events were loss of libido for the @entity1 , @entity10 and, rarely, @entity2268 . Our first experiences suggest that @entity6303 treatment is useful in cachectic @entity1 with advanced @entity957 of the head and neck.
